Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 46Neoplasms 10Prostatic Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 6Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms, Male 5Sarcoma 4Ovarian Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Stomach Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Kidney Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Wilms Tumor 2Testicular Neoplasms 2Teratoma 2

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bilateral Breast Carcinoma × ixabepilone × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡